Skip directly to content

PubMed Heart Transplant

Subscribe to PubMed Heart Transplant feed PubMed Heart Transplant
NCBI: db=pubmed; Term=heart transplant
Updated: 44 min 19 sec ago

Asialoglycoprotein receptor scintigraphy with 99mTc-galactosyl human serum albumin (99mTc-GSA) as an early predictor of survival in acute liver failure.

Wed, 07/03/2013 - 10:10
Related Articles

Asialoglycoprotein receptor scintigraphy with 99mTc-galactosyl human serum albumin (99mTc-GSA) as an early predictor of survival in acute liver failure.

Anaesth Intensive Care. 2013 Jul;41(4):523-8

Authors: Tatsumi H, Masuda Y, Imaizumi H, Yoshida S, Goto K, Yama N, Mizuguchi T, Hirata K

Abstract
This study evaluated the usefulness of asialoglycoprotein receptor scintigraphy with 99mTc-galactosyl human serum albumin (99mTc-GSA scintigraphy) as an early predictor for prognosis of acute liver failure. Forty-eight patients with acute liver failure and without a past history of chronic liver disease were enrolled. Patients were divided into survival and non-survival groups by 28-day mortality. 99mTc-GSA scintigraphy to detect uptake ratio of the heart at 15 minutes to that at three minutes (HH15) and uptake ratio of the liver at 15 minutes to the liver plus the heart at 15 minutes (LHL15), and measurements of serum total bilirubin, hepatocyte growth factor and prothrombin time were performed immediately after the diagnosis of acute liver failure. Areas under the receiver operating characteristic curves were used to compare the prognostic ability of total bilirubin, hepatocyte growth factor, prothrombin time, HH15 ratio, LHL15 ratio and the model for end-stage liver disease score. Clinical characteristics of patients in the survival group (n=20) and in the non-survival group (n=28) were not significantly different. HH15 and LHL15 uptake ratios in the survival group were 0.670 and 0.875, and they were significantly lower and higher than those in the non-survival group, respectively. All patients with LHL15 <0.760 died, and the area under the receiver operating characteristic curve for LHL15 were significantly larger than the areas under the receiver operating characteristic curves of serum variables and model for end-stage liver disease score. In summary, in patients with acute liver failure without chronic liver disease, HH15 and LHL15 of 99mTc-GSA scintigraphy are more useful variables in predicting prognosis than serum variables and model for end-stage liver disease score.

PMID: 23808513 [PubMed - in process]

How I assess comorbidities before hematopoietic cell transplantation.

Wed, 07/03/2013 - 10:10
Related Articles

How I assess comorbidities before hematopoietic cell transplantation.

Blood. 2013 Apr 11;121(15):2854-63

Authors: Sorror ML

Abstract
The hematopoietic cell transplantation-comorbidity index (HCT-CI) is a comorbidity tool suited for recipients of HCT. The index has been shown to sensitively capture the prevalence and magnitude of severity of various organ impairments before HCT and to provide valuable prognostic information after HCT. Many investigators have validated the discriminative power of the HCT-CI, but others have not. One concern is the consistency in comorbidity coding across different evaluators, particularly in view of the relatively recent addition of the HCT-CI to the transplant evaluation process. In this article, comorbidity scoring was tested across different evaluators, and only a fair interobserver agreement rate could be detected. To address these issues, a brief training program is proposed here, consisting of systematic methodology for data acquisition and consistent guidelines for comorbidity coding that were summarized in a Web-based calculator. In a validation patient cohort, this training program was shown to improve the interevaluator agreement on HCT-CI scores to an excellent rate with weighted κ values in the range of 0.89 to 0.97. This proposed training program will facilitate reliable assessment of comorbidities in the clinic and for research studies leading to standardization of the use of comorbidities in prediction of HCT outcomes.

PMID: 23355537 [PubMed - indexed for MEDLINE]

Protease-activated receptor-2 signalling by tissue factor on dendritic cells suppresses antigen-specific CD4+ T-cell priming.

Wed, 07/03/2013 - 10:10
Related Articles

Protease-activated receptor-2 signalling by tissue factor on dendritic cells suppresses antigen-specific CD4+ T-cell priming.

Immunology. 2013 Jun;139(2):219-26

Authors: Shrivastava S, Ma L, Tham el-L, H McVey J, Chen D, Dorling A

Abstract
The precise function of tissue factor (TF) expressed by dendritic cells (DC) is uncertain. As well as initiating thrombin generation it can signal through protease-activated receptor 2 (PAR-2) when complexed with factor VIIa. We investigated the expression and function of TF on mouse bone marrow (BM) -derived DC; 20% of BM-derived DC expressed TF, which did not vary after incubation with lipopolysaccharide (LPS) or dexamethasone (DEX). However, the pro-coagulant activity of DEX-treated DC in recalcified plasma was 30-fold less than LPS-treated DC. In antigen-specific and allogeneic T-cell culture experiments, the TF on DEX-treated DC provided a signal through PAR-2, which contributed to the reduced ability of these cells to stimulate CD4(+) T-cell proliferation and cytokine production. In vivo, an inhibitory anti-TF antibody and a PAR-2 antagonist enhanced antigen-specific priming in two models where antigen was given without adjuvant, with an effect approximately 50% that seen with LPS, suggesting that a similar mechanism was operational physiologically. These data suggest a novel TF and PAR-2-dependent mechanism on DEX-DC in vitro and unprimed DC in vivo that contributes to the low immunogenicity of these cells. Targeting this pathway has the potential to influence antigen-specific CD4(+) T-cell activation.

PMID: 23347132 [PubMed - indexed for MEDLINE]

Bypass surgery for lower extremity limb salvage: vein bypass.

Wed, 07/03/2013 - 10:10
Related Articles

Bypass surgery for lower extremity limb salvage: vein bypass.

Methodist Debakey Cardiovasc J. 2012 Oct-Dec;8(4):37-42

Authors: El-Sayed HF

Abstract
Bypass surgery for limb salvage in cases of chronic limb ischemia is a well-established treatment modality. Use of an autogenous vein provides the best conduit for infrainguinal arterial bypass procedures, particularly for bypass to the infrapopliteal arteries. In this article, we discuss infrainguinal vein bypass surgery including indications, perioperative care, and long-term follow up. We also discuss the outcomes of the procedure with regard to patient survival and limb salvage. The autogenous vein continues to be the best available conduit with the highest patency rate and the best treatment option. Compared to all other revascularization options for infrainguinal disease, the vein bypass has the best limb salvage and long-term survival in patients appropriately selected for the procedure.

PMID: 23342187 [PubMed - indexed for MEDLINE]

Lipid-rich versus fibrous intimal hyperplasia in transplant vasculopathy.

Wed, 07/03/2013 - 10:10
Related Articles

Lipid-rich versus fibrous intimal hyperplasia in transplant vasculopathy.

JACC Cardiovasc Imaging. 2013 Jan;6(1):126-7

Authors: Sharma R, Roleder T, Ali Z, Love BA, Kini AS

PMID: 23328571 [PubMed - indexed for MEDLINE]

Direct reprogramming of mouse fibroblasts into cardiac myocytes.

Wed, 07/03/2013 - 10:10
Related Articles

Direct reprogramming of mouse fibroblasts into cardiac myocytes.

J Cardiovasc Transl Res. 2013 Feb;6(1):37-45

Authors: Inagawa K, Ieda M

Abstract
The potency of specific transcription factors as cell fate determinants was first demonstrated by the discovery of MyoD, a master gene for skeletal muscle transdifferentiation. More recently, the induction of pluripotency in somatic cells using a combination of stem cell-specific transcription factors has been reported. That elegant study altered the approach to regenerative medicine and inspired new strategies for generating specific cell types by introducing combinations of lineage-specific transcription factors. A diverse range of cell types, such as pancreatic β-cells, neurons, chondrocytes, and hepatocytes, can be induced from heterologous cells using lineage-specific reprogramming factors. Furthermore, functional cardiomyocytes can be generated directly from differentiated somatic cells using several combinations of cardiac-enriched defined factors in the mouse. The present article reviews the pioneering and recent studies in cellular reprogramming and discusses the perspectives and challenges of direct cardiac reprogramming in regenerative therapy.

PMID: 23054660 [PubMed - indexed for MEDLINE]

Aldosterone synthase inhibition in humans.

Wed, 07/03/2013 - 10:10
Related Articles

Aldosterone synthase inhibition in humans.

Nephrol Dial Transplant. 2013 Jan;28(1):36-43

Authors: Azizi M, Amar L, Menard J

Abstract
Aldosterone synthase (CYP11B2) inhibition has emerged as a new option for the treatment of hypertension, heart failure and renal disorders, in addition to mineralocorticoid receptor (MR) blockade. The aim is to decrease aldosterone concentrations in both plasma and tissues, thereby decreasing MR-dependent and MR-independent effects in the cardiac, vascular and renal target organs. LCI699 was the first orally active aldosterone-synthase inhibitor to be developed for human use. Its structure is similar to that of FAD286, the dextroenantiomer of the aromatase inhibitor, fadrozole. It dose-dependently decreases plasma and urine aldosterone concentrations by up to 70 or 80% and increases plasma renin activity in healthy male subjects on a low-sodium diet. LCI699 does not decrease basal plasma cortisol concentrations at doses of 0.5-3 mg q.d., but it blocks the cortisol response to adrenocorticotropic hormone (ACTH) at doses ≥ 3 mg q.d. In a proof-of-concept study in patients with primary aldosteronism (PA), LCI699 (0.5-1 mg b.i.d.) induced a dose-dependent and reversible 70-80% decrease in plasma and urinary aldosterone concentration accompanied by a massive dose-dependent accumulation of deoxycorticosterone (>+700%), the aldosterone precursor, in the plasma, thereby confirming the inhibition of the CYP11B2 gene product. This effect was associated with a rapid correction of hypokalaemia, a modest decrease in blood pressure (BP) and a mild increase in plasma renin concentration in patients with PA. LCI699 administration induced biological signs of partial inhibition of the glucocorticoid axis, such as dose-dependent increases in both plasma ACTH and 11-deoxycortisol (the precursor of cortisol) concentrations, consistent with the inhibition of the CYP11B1 gene product. An 8-week placebo-controlled dose-response study on patients with Stage 1 and 2 essential hypertension reported an optimal decrease in BP with a dose of 1 mg LCI699 q.d., which had an antihypertensive effect similar to that of 50 mg b.i.d. eplerenone. A blunted cortisol response to ACTH was observed in 20% of patients, but the clinical and biological safety and tolerability of LCI699 were similar to those of placebo and eplerenone. The discovery of this first orally active aldosterone synthase inhibitor, LCI699, has provided new opportunities to assess the feasibility and the haemodynamic, biological and safety consequences as well as the limitations of this new approach to block the aldosterone pathway in hypertensive patients. However, as the effects of LCI699 on the glucocorticoid axis limit the use of higher doses range because of the loss of selectivity for CYP11B2, this aldosterone synthase inhibitor cannot replace the MR blockade in patients with hypertension, other cardiovascular or renal disorders. The development of second-generation aldosterone synthase inhibitors with a higher selectivity index for CYP11B2 than LCI699 should make it possible to test this approach at much higher doses in these patients, after the necessary toxicology and Phase I studies.

PMID: 23045428 [PubMed - indexed for MEDLINE]

Hyperkalemia: getting to the heart of the matter.

Wed, 07/03/2013 - 10:10
Related Articles

Hyperkalemia: getting to the heart of the matter.

Nephrol Dial Transplant. 2013 Jan;28(1):15-6

Authors: Welch A, Maroz N, Wingo CS

PMID: 23028106 [PubMed - indexed for MEDLINE]

The effects of age, disease state, and granulocyte colony-stimulating factor on progenitor cell count and function in patients undergoing cell therapy for cardiac disease.

Wed, 07/03/2013 - 10:10
Related Articles

The effects of age, disease state, and granulocyte colony-stimulating factor on progenitor cell count and function in patients undergoing cell therapy for cardiac disease.

Stem Cells Dev. 2013 Jan 15;22(2):216-23

Authors: Mozid AM, Jones D, Arnous S, Saunders N, Wragg A, Martin J, Agrawal S, Mathur A

Abstract
The potential of autologous bone marrow (BM)-derived progenitor/stem cell (BMSC) therapy for cardiac repair maybe limited by patient-related factors, such as age and the disease process itself. In this exploratory analysis, we assessed the impact of age, different disease states, and granulocyte colony-stimulating factor (G-CSF) therapy on progenitor cell concentration and function in patients recruited to our clinical trials of BMSC therapy for ischaemic heart failure (IHD), dilated cardiomyopathy (DCM), and acute myocardial infarction (AMI). The concentrations of CD34+ cells and endothelial progenitor cells (EPCs) were measured in the peripheral blood (PB) and BM of 201 patients. Additionally, cell mobilization following G-CSF and the functional capability of CD34+ cells (using a colony-forming unit assay) were assessed. We found that older age was associated with a lower PB CD34+ cell concentration in the whole study group as well as blunting the effect of G-CSF on BMSC mobilization in IHD patients. Nonischaemic heart failure (DCM) was associated with a significantly higher baseline PB CD34+ and EPC concentration compared to IHD. Following G-CSF treatment, the CD34+ cell concentration was greater in the BM compared to PB, however, the PB CD34+ cells appeared to have a greater and improved (compared to baseline) functional potential. Our results suggest treatment with G-CSF improves the functional potential of mobilized circulating progenitor cells compared to those in the BM. Further work is required to determine which source of cells is best for the purposes of cardiac repair following G-CSF therapy.

PMID: 22834565 [PubMed - indexed for MEDLINE]

64 slice computed tomography-a novel diagnostic method for evaluation of patients after coronary artery bypass grafts.

Wed, 07/03/2013 - 10:10
Related Articles

64 slice computed tomography-a novel diagnostic method for evaluation of patients after coronary artery bypass grafts.

Indian Heart J. 2012 Jan-Feb;64(1):23-7

Authors: Gomathi SB, Nandhini P, Ravikumar R, Ajit SM

Abstract
OBJECTIVE: Multislice computed tomography (CT) is widely used in analysing the native coronary arteries. The usefulness of 64 slice CT in patients with coronary artery bypass grafts (CABG) is analysed in the present study.
MATERIALS AND METHODS: Sixty-five patients (59 [92%] males and 6 [8%] females with the mean age of 59 ± 9.1 years) underwent 64 slice CT and a total of 186 bypass grafts (62 arterial and 124 venous grafts) were analysed using 64 slice CT. Bypass grafts and native vessels with the diameter of >1.5 mm were evaluated for the presence of significant stenosis of >70%. In all patients invasive coronary angiogram was done.
RESULTS: On the whole 43 venous grafts and 3 arterial grafts were found to be occluded. Majority of the grafts were occluded at the ostium. It was observed that the 64 slice CT was 90% sensitive and 96% specific for the evaluation of bypass grafts. It had 95% positive predictive value and 93% negative predictive value for predicting the luminal narrowing of grafts. For the assessment of arterial graft, it was 80% sensitive, 100% specific with a positive predictive value of 100% and negative predictive value of 93%. For the evaluation of venous grafts, the sensitivity, specificity, positive, and negative predictive value were 94%, 94%, 93%, and 94%, respectively.
CONCLUSION: We conclude that the 64 slice CT is a highly reliable diagnostic tool with a very high negative predictive value for evaluating patients following CABG.

PMID: 22572420 [PubMed - indexed for MEDLINE]

Route of Delivery, Cell Retention, and Efficiency of Polymeric Microcapsules in Cellular Cardiomyoplasty.

Sat, 06/29/2013 - 10:02

Route of Delivery, Cell Retention, and Efficiency of Polymeric Microcapsules in Cellular Cardiomyoplasty.

Methods Mol Biol. 2013;1036:121-135

Authors: Huu AL, Paul A, Prakash S, Shum-Tim D

Abstract
Stem cell transplantation has been considered as a major breakthrough for treating ischemic heart disease. However, survival and retention of transplanted cells at the site of infarction remains tenuous. This chapter details a method of creating polymeric microcapsules for cell delivery, resulting in increased retention of transplanted cells at the target site, while achieving minimal mechanical trauma and cell loss. Simultaneously biocompatible and biodegradable, polymeric microcapsules have important implications in regenerative cell therapy.

PMID: 23807792 [PubMed - as supplied by publisher]

Cellular Cardiomyoplasty: Its Past, Present, and Future.

Sat, 06/29/2013 - 10:02

Cellular Cardiomyoplasty: Its Past, Present, and Future.

Methods Mol Biol. 2013;1036:1-17

Authors: Lamb EK, Kao GW, Kao RL

Abstract
Cellular cardiomyoplasty is a cell therapy using stem cells or progenitor cells for myocardial regeneration to improve cardiac function and mitigate heart failure. Since we first published cellular cardiomyoplasty in 1989, this procedure became the innovative method to treat damaged myocardium other than heart transplantation. A significant improvement in cardiac function, metabolism, and perfusion is generally observed in experimental and clinical studies, but the improvement is mild and incomplete. Although safety, feasibility, and efficacy have been well documented for the procedure, the beneficial mechanisms remain unclear and optimization of the procedure requires further study. This chapter briefly reviews the stem cells used for cellular cardiomyoplasty and their clinical outcomes with possible improvements in future studies.

PMID: 23807782 [PubMed - as supplied by publisher]

Very late effects of dual chamber pacing therapy for obstructive hypertrophic cardiomyopathy.

Sat, 06/29/2013 - 10:02

Very late effects of dual chamber pacing therapy for obstructive hypertrophic cardiomyopathy.

Arch Cardiovasc Dis. 2013 Jun 24;

Authors: Lucon A, Palud L, Pavin D, Donal E, Behar N, Leclercq C, Mabo P, Daubert JC

Abstract
BACKGROUND: The very long-term effects of dual chamber pacing as a primary treatment for hypertrophic obstructive cardiomyopathy (HOCM) are poorly known and controversial.
AIMS: To examine the intermediate- and long-term clinical and haemodynamic effects of permanent dual chamber pacing in patients presenting with HOCM.
METHODS: Between 1991 and 2007, 51 patients (mean age 59±14years) presenting with HOCM and New York Heart Association (NYHA) functional class≥II despite optimal medical therapy underwent implantation of DDD pacemakers with or without a defibrillator and were followed for 11.5years (range 0.4-21.8years).
RESULTS: During follow-up, no patient underwent myectomy or septal alcohol ablation. NYHA functional class and other disease manifestations decreased significantly over 1-2years of follow-up and remained stable thereafter. The left intraventricular (LV) gradient decreased by a mean of 78% over 1-2years, reaching 89% at end of follow-up, along with disappearance of systolic anterior motion of the mitral valve. Mean LV ejection fraction decreased from a mean of 64±8% before pacing to 56±9% at end of follow-up (P=0.05), while LV end-diastolic diameter did not change significantly. The 5- and 10-year actuarial survival rates were 90% and 65%, respectively. Among 22 deaths, 10 were due to cardiovascular and 12 to non-cardiovascular causes; two patients underwent cardiac transplantation after 8 and 13years of DDD pacing, respectively.
CONCLUSIONS: In this sample of patients with HOCM, DDD pacing alleviated symptoms and improved haemodynamic function over the very long term. The merits of this treatment should be revisited in a controlled trial.

PMID: 23806305 [PubMed - as supplied by publisher]

Immunosuppression Effects on Airway Mucociliary Clearance: Comparison Between Two Triple Therapies.

Sat, 06/29/2013 - 10:02

Immunosuppression Effects on Airway Mucociliary Clearance: Comparison Between Two Triple Therapies.

Ann Thorac Surg. 2013 Jun 24;

Authors: Prado E Silva M, Soto SF, Almeida FM, Limonete TT, Parra ER, Jatene FB, Pêgo-Fernandes PM, Pazetti R

Abstract
BACKGROUND: Tacrolimus and mycophenolate have now become the most widely used combination for maintenance immunosuppressive regimens after lung transplantation in comparison with cyclosporine and azathioprine. However, limited information is available with respect to their effects on cells, other than those from the immunologic compartment. We hypothesized that different triple therapies could have different effects on airway mucociliary clearance, playing an important role in respiratory infections observed after lung transplantation.
METHODS: Ninety rats were assigned to three groups (n = 30 each): control = vehicle, therapy 1 = tacrolimus + mycophenolate + prednisone, and therapy 2 = cyclosporine + azathioprine + prednisone. After 7, 15, or 30 days of treatment by gavage, the animals were killed and the following parameters were studied: mucus transportability, ciliary beating frequency, mucociliary transport velocity, and neutral and acid mucus production.
RESULTS: There was a significant decrease in ciliary beating frequency, mucociliary transport velocity, and neutral mucus production in all immunosuppressed animals; indeed, both therapies, mainly therapy 1, caused an increase in acid mucus production for as long as 15 days of treatment.
CONCLUSIONS: Both triple therapies impaired airway mucociliary clearance of rats, but therapy 1 had a more deleterious effect. These data suggest that these undesirable effects can contribute to the high incidence of respiratory infections observed in patients undergoing lung transplantation.

PMID: 23806228 [PubMed - as supplied by publisher]

Autologous HSCT for systemic sclerosis.

Sat, 06/29/2013 - 10:02
Related Articles

Autologous HSCT for systemic sclerosis.

Lancet. 2013 Jun 15;381(9883):2080

Authors: Sakellari I, Gavriilaki E, Mallouri D, Batsis I, Anagnostopoulos A

PMID: 23769229 [PubMed - indexed for MEDLINE]

Autologous HSCT for systemic sclerosis - Authors' reply.

Sat, 06/29/2013 - 10:02
Related Articles

Autologous HSCT for systemic sclerosis - Authors' reply.

Lancet. 2013 Jun 15;381(9883):2080-1

Authors: Burt RK, Shah SJ, Schroeder J, Oliveira MC, Moraes DA, Simoes B, Marjanovic Z, Farge D

PMID: 23769228 [PubMed - indexed for MEDLINE]

Autologous HSCT for systemic sclerosis.

Sat, 06/29/2013 - 10:02
Related Articles

Autologous HSCT for systemic sclerosis.

Lancet. 2013 Jun 15;381(9883):2079-80

Authors: van Laar JM, Nihtyanova SI, Naraghi K, Denton CP, Tyndall A

PMID: 23769227 [PubMed - indexed for MEDLINE]

The total artificial heart in a cardiac replacement therapy programme.

Sat, 06/29/2013 - 10:02
Related Articles

The total artificial heart in a cardiac replacement therapy programme.

Br J Hosp Med (Lond). 2012 Dec;73(12):672-6

Authors: Barnard J, Tsui SS

PMID: 23502194 [PubMed - indexed for MEDLINE]

Screening for chronic kidney disease can be of help to prevent atherosclerotic end-organ damage.

Sat, 06/29/2013 - 10:02
Related Articles

Screening for chronic kidney disease can be of help to prevent atherosclerotic end-organ damage.

Nephrol Dial Transplant. 2012 Nov;27(11):4046-52

Authors: Özyilmaz A, de Jong PE, Gansevoort RT

Abstract
Atherosclerotic damage to the kidney is one of the most prevalent causes of chronic kidney disease and ultimately kidney failure. It frequently coincides with atherosclerotic damage to the heart, the brain and the lower extremities. In fact, the severity of the damage in the various end organs runs in parallel. As damage to the kidney is easy to measure by monitoring albuminuria and eGFR, and as the early phases of kidney damage frequently precede the alarming symptomatology in the heart, brain and peripheral vasculature, we argue that the nephrologist should consider taking the lead in better organizing early detection and management of CKD. The nephrologist can guide the general practitioner and general health care workers to offer better preventive care to the subjects at risk of progressive atherosclerotic end-organ damage.

PMID: 23144071 [PubMed - indexed for MEDLINE]

Intramyocardial Injection of Pig Pluripotent Stem Cells Improves Left Ventricular Function and Perfusion: A Study in a Porcine Model of Acute Myocardial Infarction.

Fri, 06/28/2013 - 10:21

Intramyocardial Injection of Pig Pluripotent Stem Cells Improves Left Ventricular Function and Perfusion: A Study in a Porcine Model of Acute Myocardial Infarction.

PLoS One. 2013;8(6):e66688

Authors: Li X, Zhang F, Song G, Gu W, Chen M, Yang B, Li D, Wang D, Cao K

Abstract
Induced pluripotent stem (iPS) cells have the potential to differentiate to various types of cardiovascular cells to repair an injured heart. The potential therapeutic benefits of iPS cell based treatment have been established in small-animal models of myocardial infarction (MI). We hypothesize that porcine iPS (piPS) cell transplantation may be an effective treatment for MI. After a 90-minute occlusion of the left anterior descending artery in a porcine model, undifferentiated piPS cells or PBS were injected into the ischemic myocardium. Cardiac function, myocardial perfusion and cell differentiation were investigated. One week after piPS cell delivery, global left ventricular ejection fraction (LVEF) significantly decreased in both the iPS group and the PBS group compared to the Sham group (p<0.05, respectively). Six weeks after piPS cell delivery, LVEF of the iPS group significantly improved compared to the PBS group (56.68% vs. 50.93%, p = 0.04) but was still lower than the Sham group. Likewise, the piPS cell transplantation improved the regional perfusion compared to the PBS injection (19.67% vs. 13.67%, p = 0.02). The infarct area was significantly smaller in the iPS group than the PBS group (12.04% vs. 15.98% p = 0.01). PiPS cells engrafted into the myocardium can differentiate into vessel cells, which result in increased formation of new vessels in the infarcted heart. Direct intramyocardial injection of piPS cells can decrease infarct size and improve left ventricular function and perfusion for an immunosuppressed porcine AMI model.

PMID: 23805264 [PubMed - as supplied by publisher]

Pages